|LETTER TO EDITOR
|Year : 2022 | Volume
| Issue : 1 | Page : 188
Vemurafenib plus rituximab in relapsed or refractory hairy cell leukemia
Annie Kanchan Baa, Ajay Gogia
Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
|Date of Submission||10-Jan-2022|
|Date of Decision||22-Jan-2022|
|Date of Acceptance||23-Jan-2022|
|Date of Web Publication||24-Feb-2022|
Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi - 110 029
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Baa AK, Gogia A. Vemurafenib plus rituximab in relapsed or refractory hairy cell leukemia. Cancer Res Stat Treat 2022;5:188
Tiacci et al. recently reported durable complete responses with the combination of vemurafenib plus rituximab in patients with relapsed and refractory hairy cell leukemia (HCL). Single agent rituximab is also effective in relapsed and refractory HCL. However, 55% (n = 17) of the patients in the study had not received prior rituximab therapy. Hence, independent therapeutic responses attributable to rituximab, vemurafenib, or the combination of both need to be further elucidated.
The reported incidence of the HCL variant (HCLv) in relapsed/refractory cases of HCL is 40%. HCLv has an aggressive course, and the conventional chemotherapeutic agents used in the management of HCL result in poor outcomes in cases of HCLv., HCLv has a similar morphological and immunophenotypic profile to HCL but have unmutated BRAF V600E and immunoglobulin rearrangement IGHV4-34. The efficacy of vemurafenib in unmutated BRAF V600E and IGHV4-34 is unknown. With 19% (n = 6) of cases in the current study being primary refractory to standard chemotherapy with a purine analog, it would be of interest to find out the proportion of cases with HCLv in this study and their responses.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Tiacci E, De Carolis L, Simonetti E, Capponi M, Ambrosetti A, Lucia E, et al.
Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia. N Engl J Med 2021;384:1810-23.
Thomas DA, O'Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ, et al.
Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102:3906-11.
Matutes E, Martínez-Trillos A, Campo E. Hairy cell leukaemia-variant: Disease features and treatment. Best Pract Res Clin Haematol 2015;28:253-63.
Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009;114:4687-95.